Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5489.

https://doi.org/10.1182/blood-2019-123179

Published: 2019

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

David Andorsky, MD, Rebecca J Chan, MD PhD, Jamyia Clark, MPH, Bianca Ruzicka, PhD, Nicholas James Robert, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 2810.

https://doi.org/10.1182/blood-2019-124013

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

A Multicentre, Retrospective Observational Study to Evaluate the Clinical Outcomes of Patients with Chronic Lymphocytic Leukaemia (CLL) Treated with Idelalisib and Rituximab in the UK (RETRO-idel) - a Cohort of 110 Patients

Toby A. Eyre, Gavin Preston, MD, Huseini Hatimbhai Kagdi, MD PhD MBBS, FRCPath, MRCP, Amin Islam, MD, Toby Nicholson, FRCPath, MBBS, MRCP, BA, Christopher Fegan, MB, MD FRCP, FRCPath, Harry W Smith, BSc, MSc, Adam P Cursley, MSc, Heribert Ramroth, PhD, Nishan Rajakumaraswamy, MD

Blood (2019) 134 (Supplement_1): 1762.

https://doi.org/10.1182/blood-2019-126845

Published: 2019

Journal Articles

Diagnosis of Lung Complication in Allogeneic Stem Cell Transplantation By Combined Use of Multiple Methods through Bronchoscopic Alveolar Lavage

Su Li, master's degree, Xianmin Song, MD, Liping Wan, Chun Wang, Yin Tong, Master's degree, Chongmei Huang, MD, Xiaoqian Xu, Master's degree, Yu CAI, MD, Guogang Xie, MD, Rong Tang, MD, Yi Sun, PhD, Aihua Bao, MD, Jun Yang, MD

Blood (2019) 134 (Supplement_1): 4626.

https://doi.org/10.1182/blood-2019-127950

Published: 2019

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Scott Wirth, PharmD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2018-99-117657

Published: 2018

Journal Articles

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Francesco Autore, MD, Idanna Innocenti, MD PhD, Francesca Morelli, Federica Sora, Andrea Corbingi, MD, Denise Soldati, Luana Fianchi, MD, Marianna Criscuolo, Livio Pagano, Andrea Bacigalupo, MD, Simona Sica, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5552.

https://doi.org/10.1182/blood-2018-99-119654

Published: 2018

Journal Articles

Prophylaxis of Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia in Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Single Center Experience

Joo Young Ha, MD, Kyoungmin Lee, MD, Jung Yong Hong, Dok Hyun Yoon, Sung-Han Kim, Seongsoo Jang, Chan-Sik Park, Jooryung Huh, Jin-Sook Ryu, Sang-wook Lee, Cheolwon Suh

Blood (2018) 132 (Supplement 1): 5832.

https://doi.org/10.1182/blood-2018-99-118360

Published: 2018

Journal Articles

Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program

Loic Ysebaert, MD PhD, Pierre Feugier, Gilles Andre Salles, MD PhD, Eric Durot, MD, Alexis Talbot, MD, Choquet Sylvain, MD, Denise Glorian Kergaravat, Alastair Simpson, Heribert Ramroth, Tarek Abdelhadi, Corinne Haioun, MD, Xavier Troussard, MD

Blood (2018) 132 (Supplement 1): 5924.

https://doi.org/10.1182/blood-2018-99-110766

Published: 2018

Journal Articles

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Ian W. Flinn, MD PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Zoltán Gasztonyi, MD, Matthew S. Davids, MD, Klaus Geissler, MD, Jose J. Rifon Roca, MD, Leanne Berkhan, ADHB, Fritz Offner, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Julio Delgado, MD

Blood (2018) 132 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2018-99-120027

Published: 2018

Journal Articles

Rituximab for Immune Thrombocytopenia: A Retrospective Analysis on the Role of Prophylaxis Against Pneumocystis Jirovecii and Herpes Zoster Virus

Simona Raso, MD, Mariasanta Napolitano, MD PhD, Melania Carlisi, MD, Salvatrice Mancuso, MD, Marco Santoro, MD, Sergio Siragusa, MD Professor

Blood (2018) 132 (Supplement 1): 4992.

https://doi.org/10.1182/blood-2018-99-118585

Published: 2018

Journal Articles

Real-Word Clinical Management of Patients Treated with Idelalisib in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL)

Anne-Sophie Michallet, MD PhD, Emmanuel Gyan, MD PhD, Pierre Feugier, Ana Nunes, PharmD, Tarek Abdelhadi, Loic Ysebaert, MD PhD, Stéphane Leprêtre, MD

Blood (2018) 132 (Supplement 1): 2302.

https://doi.org/10.1182/blood-2018-99-113476

Published: 2018

Journal Articles

Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2018-99-118896

Published: 2018

Journal Articles

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Tycel J. Phillips, Andres Forero-Torres, Taimur Sher, Catherine S. Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M. Barr

Blood (2018) 132 (3): 293–306.

https://doi.org/10.1182/blood-2017-10-812701

Published: 2018

Includes: Supplemental data

Journal Articles

Diagnostics of Pulmonary Aspergillosis in Critically Ill Hematological and Non-Hematological Patients in the Intensive Care Unit By Combined Use of Galactomannan, 1-3-Beta-D-Glucan, Aspergillus Specific PCR and Conventional Culture in Concurrent Blood and Bronchoalveolar Lavage Samples — Results of a Multicenter Prospective Pilot Study

Tobias Boch, MD, Birgit Spiess, Tobias Liebregts, Peter Schellongowski, Patrick Meybohm, Peter-Michael Rath, Jörg Steinmann, Simone Britsch, Jabbour Claude, Julia Michels, Wolf-Karsten Hofmann, MD, Mark Reinwald, Dieter Buchheidt

Blood (2017) 130 (Supplement 1): 3456.

https://doi.org/10.1182/blood.V130.Suppl_1.3456.3456

Published: 2017

Journal Articles

Pneumocystis Jiroveci Pneunomia Prophylaxis during Maintenance Therapy with Hyper-CVAD Regimens for Adult Acute Lymphoblastic Leukemia

Grace A. Martin, PharmD, Shilpa Paul, PharmD, Wei Qiao, PhD, Elias J. Jabbour, MD, Dimitrios P. Kontoyiannis, MD, Deborah A. McCue, PharmD

Blood (2017) 130 (Supplement 1): 1295.

https://doi.org/10.1182/blood.V130.Suppl_1.1295.1295

Published: 2017

Journal Articles

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Benjamin Tillman, MD, James Michael Pauff, MD PhD, Gowri Satyanarayana, MD, Mahsa Sharifi Talbott, PharmD, Jeremy Warner, MD MS

Blood (2017) 130 (Supplement 1): 3460.

https://doi.org/10.1182/blood.V130.Suppl_1.3460.3460

Published: 2017

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

NARROW

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

A Multicentre, Retrospective Observational Study to Evaluate the Clinical Outcomes of Patients with Chronic Lymphocytic Leukaemia (CLL) Treated with Idelalisib and Rituximab in the UK (RETRO-idel) - a Cohort of 110 Patients

Diagnosis of Lung Complication in Allogeneic Stem Cell Transplantation By Combined Use of Multiple Methods through Bronchoscopic Alveolar Lavage

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Prophylaxis of Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia in Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Single Center Experience

Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Rituximab for Immune Thrombocytopenia: A Retrospective Analysis on the Role of Prophylaxis Against Pneumocystis Jirovecii and Herpes Zoster Virus

Real-Word Clinical Management of Patients Treated with Idelalisib in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL)

Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Pneumocystis Jiroveci Pneunomia Prophylaxis during Maintenance Therapy with Hyper-CVAD Regimens for Adult Acute Lymphoblastic Leukemia

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only